(Date:12/2/2009)...-Asia/ -- The world is going through,extraordinary...part of many,businesses and industries. It turns o...mune to the economic downturn, because illness doe...of the difficult times this year, the pharmaceutic...p;D center in Shanghai, the largest of,its kind in...
(Date:12/1/2009)...swire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nas...the fourth quarter ended December 31, 2009 of appr...n for the fourth quarter of 2008. Included in four...llment payments of $12.5 million from Alexion. Al...ne-time $1.8 million payment from Genentech for th...
(Date:12/1/2009).../ -- Harvest Technologies Corp. ( www.harvesttech....nsored 60-patient clinical trial conducted at Sri ... the company,s BMAC System to treat patients with ...Sri Ramachandra Medical Center is a Harvard Medica...ennai, India and one of the largest private health...
(Date:12/1/2009)...e/ -- Expanding its European reach for bacterial p...ppointed Lake Chemicals and Minerals of England as...gham, England. ,, Osprey breeds trillions of b...aste water, and environmental markets. Its bacteri...and clean up industrial and marine spills. In agri...
Breaking Biology Technology:Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3...llars, QUEBEC CITY, Nov. 13 /PRNewswire-FirstCall...Z), a global biopharmaceutical company focused on,...al and operating results,for the third quarter end...ights, - Appointment on September 1, 2008, of Jue...na Zentaris, replacing Juergen Ernst who had been ...
...eduction in loss for the quarter, SAN JOSE, Calif...lletin Board: EROX) ("HPS" or "the Company") today...months ended September 30,2008. For the three mont...f,$262,000 represented a 10% increase from the rev...sulted in a net loss of $30,000 ($.01 per share),a...
...s professor Apparao Rao and his team are researchi...to read and alert us to toxic chemicals or gases i...nd the potential is there for real-time chemical a...ven at home. , "The ability to build extremely sm...ve only seen so far in science-fiction movies," Ra...
Other Biology Technology:AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 2AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 3AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 4AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 5AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 6AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 7AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 8AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 9Human Pheromone Sciences Announces Third Quarter Results 2Human Pheromone Sciences Announces Third Quarter Results 3Human Pheromone Sciences Announces Third Quarter Results 4Clemson researchers advance nanoscale electromechanical sensors 2Anti-G Protein Gi-alpha-1 Monoclonal Antibody, Unconjugated, Clone R4 from CHEMICON
Anti-VEGF Receptor-2 (FLK-1, KDR), phospho (Tyr996) Antibody, Unconjugated from CHEMICON
Rat IgG2b Clone: A95-1, Allophycocyanin Conjugated/Tagged from BD Biosciences Pharmingen
Mouse Oligodendrocyte Differentiation Kit from R&D Systems
Biology Products: